Lantern Pharma
NASDAQ: LTRNDallas, US · Founded 2013 · Texas corporation · 32 employees on LinkedIn · 2 known investors
Find your way into Lantern Pharma
136 people in our graph share verified history with the Lantern Pharma team — schools, employers, funds. One of them is your warm intro.
Aydin Senkutunlockedknows Panna Sharma · together at Boston University (overlapped)
×3knows the team · via iXL
×6knows the team · via Boston University
×2knows the team · via Bank of America
Lantern Pharma is a pharmaceutical biotechnology company that applies machine learning and AI to oncology drug development, using data-driven hypothesis testing with in vitro and in vivo models. Its approach stratifies patient populations into responders and non-responders to de-risk clinical trials, develop companion diagnostics, and improve the likelihood of FDA approval at reduced cost.
Founders & leadership
Lantern Pharma was founded in 2013 by Arunkumar Asaithambi.
AA
Arunkumar AsaithambiFounder
DR
David R. MargraveinChief Financial Officer
PS
Panna SharmainChief Executive Officer, President and Board MemberPanna Sharma leads Lantern Pharma as CEO and President. She brings extensive experience in biotech and emerging technology companies across business development, capital raising, and strategic transactions, with a focus on oncology, drug development, and AI applications in personalized medicine.
KG
Kishor G. BhatiainChief Scientific Officer
DK
David KeyserNamed on SEC filing
JF
John FucciNamed on SEC filing
Board
DJ
Donald Jeffrey KeyserChairman of the Board
LT
Lee T. SchalopBoard director
VC
Vijay ChandruBoard director
DS
David S. SilbersteinBoard director
MM
Maria MaccecchiniBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$2.9M disclosed across 2 of 4 rounds · 1900–2026
▶Undisclosed amountofferedMay 2026 · 6 investors · PharmaceuticalsRule 506(b)
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine - BioSpacebiospace.com · Aug 2026
Lantern Pharma spins out AI platform into Open-Medicine AI By Investing.comca.investing.com · Aug 2026
▶Undisclosed amountofferedMay 2026 · 6 investors · Pharmaceuticals
Rule 506(b)Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine - BioSpacebiospace.com · Aug 2026Officers, directors & promoters on the filing
- Donald Jeffrey KeyserDirector
- David R. MargraveExecutive Officer
- Panna SharmaExecutive Officer, Director
- Kishor G. BhatiaExecutive Officer
- Lee T. SchalopDirector
- Vijay ChandruDirector
- David S. SilbersteinDirector
- Maria MaccecchiniDirector
- First sale
- May 2026
- Incorporated
- Corporation, Texas
- Federal exemptions
- 06b
▶$2.4MraisedMar 2019 · 5 investors · BiotechnologyRule 506(b)
▶$2.4MraisedMar 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David SilbersteinDirector
- John FucciDirector
- Arunkumar AsaithambiDirector
- Panna SharmaExecutive Officer, Director
- Donald KeyserDirector
- Offering amount
- $6.3M
- Amount sold
- $2.4M
- Proceeds to insiders
- $360K
- First sale
- Mar 2019
- Incorporated
- Corporation, Texas
- Federal exemptions
- 06b
▶$535KraisedJan 2019 · 5 investors · BiotechnologyRule 506(b)
▶$535KraisedJan 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David SilbersteinDirector
- Panna SharmaExecutive Officer, Director
- Arunkumar AsaithambiDirector
- David KeyserDirector
- John FucciDirector
- Offering amount
- $535K
- Amount sold
- $535K
- First sale
- Dec 2018
- Incorporated
- Corporation, Texas
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Lantern Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine - BioSpacebiospace.com · Aug 2026
Lantern Pharma (NASDAQ: LTRN) files S-1 resale and flags funding riskstocktitan.net · Jun 2026Frequently asked questions
- What does Lantern Pharma do?
- Lantern Pharma is a pharmaceutical biotechnology company that applies machine learning and AI to oncology drug development, using data-driven hypothesis testing with in vitro and in vivo models. Its approach stratifies patient populations into responders and non-responders to de-risk clinical trials, develop companion diagnostics, and improve the likelihood of FDA approval at reduced cost.
- Who founded Lantern Pharma?
- Lantern Pharma was founded by Arunkumar Asaithambi in 2013.
- Who are Lantern Pharma's investors?
- Lantern Pharma's investors include Green Park & Golf Ventures, Health Wildcatters.
- How much funding has Lantern Pharma raised?
- Lantern Pharma has disclosed $2.9M raised across 2 of its 4 known rounds.
- Where is Lantern Pharma headquartered?
- Lantern Pharma is headquartered in Dallas, US.